Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has announced a significant milestone in its ACCENT trial, which is evaluating the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has recorded a second complete response, a rare outcome in this disease, highlighting the potential of narmafotinib to enhance treatment efficacy and improve patient outcomes. This development underscores Amplia’s progress in targeting fibrotic cancers and solidifies its position in the oncology sector.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company focuses on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 2,267,737
Technical Sentiment Signal: Sell
Current Market Cap: A$25.6M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.